Top Markets:

United States: Holding the largest share with approximately 42.6% of the global market in 2022.
China: Experiencing rapid growth and currently holding around 7.6% of the market (hospital segment only).
Japan: A mature market with a 4.5% share.
Germany: Another mature market contributing 4% to the global total.
France: Rounding out the top 5 with a 3.8% share.

Why would you choose the UK over US or even the EU for that matter? Size, hell no.

Legitmacy...laughable.

Scared they would get rejected if they tried the US first...most likely that's why they waited for this JAMA to explain the mess of the trial results and needed additional support of another RA. Oh and also they thought building the facility in the UK (for the CEO's fund at the expense of NWBO shareholders) might have helped their case. I hope to hell this never-ending scam for any real naive invested retails ends soon.





PHARMACEUTICAL MARKET VALUE (at ex–factory prices) EFPIA 2020 € million € million Austria 4,827 Belgium 6,303 Bulgaria 1,414 Croatia 1,036 Cyprus 177 Czech Rep. 3,389 Denmark 3,243 Estonia 359 Finland 2,762 France 29,552 Germany 42,962 Greece 5,381 Hungary 2,558 Iceland 183 Ireland 2,354 Italy 23,446 Latvia 275 Lithuania 866 Malta 196 Netherlands 6,185 Norway 2,597 Poland 7,239 Portugal 3,524 Romania 4,500 Russia 18,398 Serbia 871 Slovakia 1,461 Slovenia 743 Spain 17,604 Sweden 4,570 Switzerland 5,920 Turkey 6,626 U.K. 24,569


There is a reason it is usually in this order when seeking approval: US, EU, Japan. Lately, China is being thrown somewhere in that mix. You shouldn't wonder why when you look at the revenue size. Unless you drink this company's kool aid or paid by them to pump this crap.

Buyout based on UK alone, you ain't going to get much. The real BO always has and always will go through the US. You don't get that US RA, you ain't getting squat especially with that 1.7B authorized share count.

size have you seen the percentage of revenue derived from UK? Do you know why this is low? Mainly because of reimbursement and partly because of the size of the market. You drink this kool-aid when there are facts that show this. But OK, let's go with 45% penetration of CNS Market. LMFAO. Anyone that supports this UK first move is a clown. Legitmacy? FDA is not influenced by UK. GTFOOH.

Why do all the paid pumpers have $ next to their names. SMFH.

This what BP does sink a little money into these companies and watch if they pan out.

speculation that it is high probability of approval---plain hopium, we can soon find out if what you say is correct. 150 days or 5 months is actually May 21st, 2024 if what the company and the true longs say is correct about the 150 day process. So don't need to speculate one way or the other. WWSH. Let's check then instead of spreading hopium and unecessary speculation about probability of approval.

A total idiot would be to dismiss negative narratives with blinders on and not have the ability see that these individuals who were part of this are still with the company and to this day continue to self deal and enrich themselves. True longs claim it is 10 years old and LP had nothing to do with it. It is just shorts and fudster nonsense they argue. Why no counter argument instead you get name calling and fudster arguments. Why would the company be so bothered about it? Laughable and predictable AF responses by the paid true longs. Are you true longs 5 years old and think fudster and short name calling is effective?? Oh nevermind this is this is the battle cry your fearless leader and self dealing LP implored you to do at the last ASM. LMFAO.

This is what happens In a cult. If you are in it and a true retail,, I pray for you that you are able to get out on thr next pump.

So you you think him posting on this message board is on the up and up? Just way too many red flags/fleas to count on this dog of a company .....

Can you even believe that story though? Why would he not be buying directly from NWBO. That story doesn't even make any sense whatsoever.

So this insider admitted shares were funneled into Navid. Yeah you are right, there can be no reason or justification for an analyst to be taking shares. This is just some shady sht beyond belief. The deeper you dig into this, the more shady sht you find. No wonder the company works so hard to shut up any critics with their social media aliases or true longs nonsense. This is just a total scam.

https://www.fiercebiotech.com/biotech/exceptional-survival-data-lower-costs-key-to-competitive-advantage-of-dcvax-r-northwest

Here is another pump with LP and "analyst" Malik Navid. No wonder he has millions of dollar worth of nwbo. He was a paid to pump and now is a board member. And the true longs say he was before LPs time. SMFH.


The sooner you realize these nwbo c suite are crooks to enrich themselves the better off you will be.

This chartist is right how many times? Sorry man dude has bias in his charting. I don't ever see him recommending a sell. This stock is under all major moving averages which is a no go brother in simple terms. And stock can also break down out of that wedge. He doesn't have any outstanding qualities that I've seen. If he was experienced, he would know better than investing in a broke OTC company with dilution problems.

Sure brother here you go!

Here is one where Stanford already resected and sent it to Philly. The good part is they said they were ready to launch and they aren't wasting time.

The #TIL team at @StanfordCancer did our first surgical tumor harvest for AMTAGVI (lifileucel) this morning! The tumor is en route to Philadelphia for TIL expansion. Incredibly proud of our team for the work we have done to be ready to deliver this therapy ASAP. Cell therapy for… pic.twitter.com/WGPe0Z3ymL

— Allison Betof Warner, MD, PhD (@DrBetofMDPhD) February 20, 2024

Update in #melanoma #TIL news: lifileucel PDUFA date pushed back to Feb 2024 due to delays on the @FDAOncology end. This isn’t a problem with the data etc.

This is a huge hit to patients desperately waiting for this lifesaving treatment. We already have waitlists and now there…

— Allison Betof Warner, MD, PhD (@DrBetofMDPhD) September 14, 2023

well i'm make sure to deliver your eulogy when the end is here.

Maybe you will learn your lesson and not invest in POS OTC next time if you have any spare change left.

The make believe that these true longs come up with is really ridiculous. Look at the stupid short interest numbers, it account for like a pittance of the Authorized and Float. The breadcrumbs never stop. What are you expecting for the Shorts to make....Pennies? Sorry there is no evidence there is any sizable short position worth mentioning. Stop making this crap up. I feel sorry for anyone that believes this propoganda these True longs put out.

How long can you really keep hope alive before you realize it is a POS. I guess they just keep trying to fool another new set of green retail investors with this this cult-level BS so they can dilute into.

oh sorry, i misquoted my gain it is 410K, not 400k in profits. Sorry a liar is something i'm not.

Sorry kid, don't invest in garbage.

https://investorshub.advfn.com/uimage/uploads/2024/2/21/xinfqiova_pos.png

why would i complain. i'm up over 400k in iova profits.

This is why you invest in real legit companies that can execute instead of giving out $Millions of dollars to directors and building out an external CDMO for the CEO and her fund using NWBO Funds at the expense of submitting an application.

Did you see that Stanford already resected a patient and sent it off to philly for the drug. The Dr said back in September they already had a wait list of patients for it be approved.

I don't what can be considered worse. The person who wrote that diatribe of true long sleeper cells or the cult members who liked it.

At $10 per share with fully authorized is 17b market cap hahaha. The cult lives on. A lot of these people just see share price thats why they buy this thinking it is cheap. But they don't consider there are 1.7b fully authorized shares and if there is a buyout you can be rest assured fully authorized becomes the share count.

Whatever happened to those uplisting specialists that were hired? More planted breadcrumbs by the disciples that never seem to pan out but are meant to keep retail interest
alive? Maybe they were advised they need to address these ongoing sec violations first before even considering uplisting? Related party transactions can't really be explained to this day. Not a good look.

Instead of name calling, can you tell me how nwbo addressed these sec violations that they paid a fine for?

To Uplist, can the SEC forgive the past and ongoing indiscretions that led them to delist in the first place? Untimely reporting, no accounting governance in place, self dealing related party transactions.....all still seem to be true to this day.

Is this the sad rebuttal you do, read the journal article. Nice try Bala Jr.

The claim that they can project CNS for their projections is absurd and at a 45% clip to boot. And to think that insurance would cover it let alone doctors would recommend this. Please cultists get off the hopium.

Resort to name calling when you can't refute a valid argument. Good one hoff.

That is realistic? 45% penetration on the CNS market? Sorry brother but there will be no off label insurance coverage. This will be strictly on label and will need prior authorization. And the UK is notorious for not covering drugs or pricing them at a huge discount. The reason why the US market is bigger is because of the size,insurance coverage, and premium pricing. You don't have a clue how insurance works do you. 20b market cap based on UK wtf are you smoking. Jesus, you talk about hopium .....this tops the cake.

This approval getting lot of eyes on it.

Have you looked at car-t and til data before you make up this crap? These therapies have lot of CRs in the 1L setting. Yall cultists act Iike you are about cancer patients but when push comes to shove prove you all are just butt hurt haters and nwbo cultists with blinders on. This company didn't even understand their endpoints and tried to change the design after bias. Sorry buddy that's what phase 2 is about. Yall need to go back and prove out this design in phase 2. Oh but you can't because you are broke.


Keep on believing in the self dealing at the expense of shareholders and hence the never ending story of pump and dilute. Maybe next year or the year after if NWBO is still a going concern. Keep the breadcrumbs to keep retail interested to pump into.

When was it accepted? I think the MHRA said it was filed only upon verifying NWBO revealed that information first themselves. No one knows that it was actually accepted.

Flip you know what matters here. It is to get the aproval so they can start generating revenue instead of this selling shares practically everyday to pay for bills and Advent. All the patents in the world are meaningless unless they get approval. I'm waiting for when LP is going to ask for more "Authorized Shares", because it is coming. ASM announcment is going to come after some kind of announcement, and I'm guessing that would be "Application Acceptance".

YES NWBO, i know you read this MB, and I know what you are going to do before you do it! Time to start showing some urgency in generating revenue, and that starts first by submitting an accepted Application!

It gotta mostly be the company doing this pumping and trying to silence criticisms to keep retail liquidity. And then just a few retail are doing it too. The OTC investors think they can buy things for pennies and are going to be rich. This is where money comes to die for the most part. They will FAFO.

The loudest silencing is when the conflict of interest Toucan/Advent is brought up because that is clear as day self-dealing. They can't argue it at all. They talk about lease and equipment BS, but their argument can't tread water.

Flip is this alphavestcapital guy you, it looks word for word like your post here. You get paid twice one for here and one for x.com? Or is the the script the company gave you guys? Sorry you and dstock that Rookie are butt hurt about another autologous getting fda approval while you guys can't even get little market MHRA to accept your application probably because they need additional work from who else NWBO. Can't ever get anything done right or in a timely fashion.

In the meanwhile, keep posting those patents.....they may help if this ever gets approved.

And maybe now that NwBO understands their endpoints, they can design a new trial when the RAs reject the application asking for a new trial. Oh but wait, nwbo is broke. Maybe some one else can run it.

📷https://t.co/fB91h7Nw1k $nwbo @alphavestcap

Melanoma, even metastatic melanoma, is one of the most immunogenic cancers. TIL therapy requires nonmyeloablative lymphodepletion. Wiping out other T-cells prior to reintroduction of t-cells.

TIL therapy, like that of Lifileucel,…

— alphavestcapital.com (@alphavestcap) February 17, 2024

This belief supports there is paid social media to refute criticisms. LP unbelievably asked for this help in the ASM. Instead of focusing on what the company needs to accomplish, she needs to push this narrative of MM manipulation. This is unreal and pathetic.

Could it also be:

4. The company is paying social media disciples to refute criticisms so they can dilute?


Things that make you go hmm. Recall at the last ASM LP did mention this.

https://www.nbcnews.com/nightly-news/video/the-fda-has-just-approved-a-new-kind-of-therapy-for-a-deadly-form-of-skin-cancer-it-s-a-treatment-using-a-patient-s-own-cells-and-it-could-transform-the-future-of-treating-advanced-tumors-nbc-s-anne-thompson-reports-204387397571

https://abcnews.go.com/WNT/video/fda-approves-new-therapy-melanoma-107308894

https://www.nbcnews.com/nightly-news/video/the-fda-has-just-approved-a-new-kind-of-therapy-for-a-deadly-form-of-skin-cancer-it-s-a-treatment-using-a-patient-s-own-cells-and-it-could-transform-the-future-of-treating-advanced-tumors-nbc-s-anne-thompson-reports-204387397571

Not only NPR, but also cnbc has coverage. The PRs keep coming. Time to squeeze them shorts.

https://www.nbcnews.com/health/health-news/fda-approves-groundbreaking-treatment-advanced-melanoma-rcna138005

https://www.npr.org/2024/02/17/1232247301/melanoma-fda-approves-first-cell-therapy-skin-cancer

https://www.abc12.com/news/fda-approves-new-therapy-for-hard-to-treat-metastatic-melanoma/article_28b43ab2-6fa7-5b89-9c61-fbb679e5cfb7.html

https://www.cbsnews.com/philadelphia/news/fda-approved-cancer-treatment-melanoma-md-anderson-cooper-camden-debra-marsdale/

https://www.fda.gov/news-events/press-announcements/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma

https://www.cnn.com/2024/02/16/health/metastatic-melanoma-treatment-amtagvi/index.html

https://www.biospace.com/article/an-fda-approval-for-iovance-could-jumpstart-40-year-old-field-/

https://www.fiercepharma.com/pharma/fda-approves-iovances-amtagvi-first-cell-therapy-solid-tumor

https://thehill.com/policy/healthcare/4474354-fda-approves-first-cellular-therapy-to-treat-advanced-melanoma/

Moffitt Cancer Center is excited to share that the @US_FDA has approved a groundbreaking TIL therapy for advanced melanoma. As leaders in immunotherapy, we are working to unlock the potential it holds for many more solid tumors.

Read more: https://t.co/epPk2YQw0Y@NBCNews

— Moffitt Cancer Center (@MoffittNews) February 16, 2024

The FDA has approved a groundbreaking treatment for advanced melanoma. @DanaFarber’s Elizabeth Buchbinder, MD (@bbuchbinderMD) tells NBC, “This is going to be huge.”
Read more:https://t.co/LXmcpf6tJl

— Dana-Farber News (@DanaFarberNews) February 16, 2024

no revenue split with the ceo's owned cdmo........